Challenged; SEC denied. 60.53% in favor
Resolution urging Board of Directors to report to shareholders by June 30, 2019, describing the corporate governance changes Walgreens has implemented since 2012 to more effectively monitor and manage financial and reputational risks related to the opioid crisis, including whether and how the board oversees Walgreens’ opioid-related programs and AmerisourceBergen’s opioid-related risks, whether the crisis has been designated (or is encompassed within) a material corporate social responsibility issue and whether and how Walgreens has changed senior executive incentive compensation arrangements.
We and selected third parties use cookies or similar technologies for technical purposes and, with your consent, for other purposes. You can consent to the use of such technologies by using the “Accept” button, by closing this notice, by scrolling this page, by interacting with any link or button outside of this notice or by continuing to browse otherwise.